Insmed presents broad range of data across its three programs at the american thoracic society 2021 international conference

Bridgewater, n.j., may 19, 2021 /prnewswire/ -- insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported data from a total of nine posters and oral presentations across its three programs—arikayce, brensocatib, and treprostinil palmitil inhalation powder (tpip)—at the virtual american thoracic society (ats) 2021 international conference.
INSM Ratings Summary
INSM Quant Ranking